Uniphar PLC

Board/Management Information • Apr 21, 2020

National Storage Mechanism | Additional information

RNS Number : 2673K

Uniphar PLC

21 April 2020

Director Resignation

Dublin, London | 21 April 2020

Uniphar plc (the "Company") wishes to announce that John Holly has informed the Board that he will not put himself forward for re-election at the forthcoming AGM following ten years' service on the Board and the successful IPO in July 2019. His resignation will take effect immediately following the Company's AGM.

Maurice Pratt, Chairman of Uniphar plc, commented:

"I would like to personally thank John for the very significant contribution he has made as a Board member over the past decade, and to wish him well in the future."

--- ENDS ---

For further details contact:

Uniphar                                                                                    Brian O'Shaughnessy Group Director of Corporate Development	+353 (0) 1 428 7777 investor.relations@Uniphar.ie
Davy (Nominated Adviser and Euronext Growth Adviser)      Fergal Meegan Barry Murphy Tom Tynan	+353 (0) 1 679 6363

About Uniphar plc

Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,200, the Group is active in Ireland, the UK, the Benelux, the Nordics and the US.

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.

Commercial & Clinical 

In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in Ireland, the UK, the Benelux and the Nordics, the Group is growing with clients to provide pan-European solutions. Uniphar have built a fully integrated multi-channel solution that is supported by highly experienced, clinically trained teams to deliver exceptional outcomes for all clients.

Product Access 

In Product Access the Group is growing two distinct service offerings: 1) "On-Demand Access", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions to more than 160 markets globally.

Supply Chain & Retail 

Uniphar is an established market leader in Ireland with c50% supply chain market share supported by a network of 287 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the assets and infrastructure are utilised for the benefit of the growth divisions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAEAELEAFEEEAA